Indus Capital Partners, LLC Argenx Se Transaction History

Indus Capital Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$254.45 - $351.06 $7.48 Million - $10.3 Million	-29,383 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$257.11 - $319.92 $1.48 Million - $1.84 Million	-5,749 Reduced 16.36%	29,383 $8.85 Million
Q1 2021 May 14, 2021	BUY	$268.3 - $380.31 $1.98 Million - $2.81 Million	7,390 Added 26.64%	35,132 $9.68 Million
Q4 2020 Feb 16, 2021	SELL	$248.13 - $308.36 $4.17 Million - $5.18 Million	-16,808 Reduced 37.73%	27,742 $8.16 Million
Q3 2020 Nov 13, 2020	SELL	$215.51 - $272.51 $15.2 Million - $19.2 Million	-70,346 Reduced 61.23%	44,550 $11.7 Million

Q2 2020 Aug 13, 2020	SELL	$127.44 - $232.72 $8.73 Million - $15.9 Million	-68,488 Reduced 37.35%	114,896 $25.9 Million
Q1 2020 May 15, 2020	BUY	$108.83 - $165.23 $11.3 Million - $17.2 Million	104,289 Added 131.85%	183,384 $24.2 Million
Q4 2019 Feb 14, 2020	BUY	$106.59 - $164.21 $8.43 Million - $13 Million	79,095 New	79,095 $12.7 Million

356

31.3M

212K

210K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $25.3B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Indus Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Indus Capital Partners, LLC with notifications on news.